Arrowhead (ARWR) announced preclinical results on ARO-ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback